RecruitingNot ApplicableNCT05899842

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia. Randomized Open-label Clinical Trial


Sponsor

Centre Hospitalier Universitaire de Nīmes

Enrollment

132 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patient with an indication for esophageal POEM for achalasia
  • Patient with all types of achalasia with Eckardt score > 3
  • The patient must have given their free and informed consent and signed the consent form
  • The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria8

  • Patient with contraindications to PPIs
  • Patient with mediastinal and esophageal neoplasia
  • Patient with a history of Heller myotomy surgery
  • Patients requiring any type of anti-reflux valve surgery
  • The subject is in a period of exclusion determined by a previous study
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship
  • Patient is pregnant, parturient or breastfeeding

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGProtein pump inhibitor therapy systematically

Lansoprazole 30mg once per day


Locations(4)

AP-HM

Marseille, France

CHU de Montpellier

Montpellier, France

Clinique mutualiste Beausoleil

Montpellier, France

CHU de Nîmes

Nîmes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05899842


Related Trials